SG10201913260VA - Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same - Google Patents

Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same

Info

Publication number: SG10201913260VA
Authority: SG; Singapore
Prior art keywords: preparing; same; heterodimeric bispecific; antibody; bispecific antibody
Prior art date: 2016-11-18

Application number

SG10201913260VA

Inventor

Jiawang Liu

Nanmeng Song

Yaping Yang

Maengsup Kim

Original Assignee

Beijing Hanmi Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-18

Filing date

2017-11-16

Publication date

2020-03-30

2017-11-16 Application filed by Beijing Hanmi Pharmaceutical Co Ltd filed Critical Beijing Hanmi Pharmaceutical Co Ltd

2020-03-30 Publication of SG10201913260VA publication Critical patent/SG10201913260VA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10201913260VA 2016-11-18 2017-11-16 Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same SG10201913260VA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN201611016435		2016-11-18

Publications (1)

Publication Number	Publication Date
SG10201913260VA true SG10201913260VA (en)	2020-03-30

Family

ID=62146170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201913260VA SG10201913260VA (en)	2016-11-18	2017-11-16	Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same

Country Status (19)

Country	Link
US (1)	US11319378B2 (en)
EP (1)	EP3533804A4 (en)
JP (1)	JP7031810B2 (en)
KR (1)	KR102247704B1 (en)
CN (1)	CN109963876B (en)
AU (1)	AU2017359813B2 (en)
BR (1)	BR112019010051A2 (en)
CA (1)	CA3043652A1 (en)
CL (1)	CL2019001352A1 (en)
CO (1)	CO2019005101A2 (en)
DO (1)	DOP2019000124A (en)
EA (1)	EA201990894A9 (en)
EC (1)	ECSP19035482A (en)
MX (1)	MX2019005858A (en)
PE (1)	PE20191080A1 (en)
PH (1)	PH12019501089A1 (en)
SG (1)	SG10201913260VA (en)
TN (1)	TN2019000161A1 (en)
WO (1)	WO2018090950A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL265605B2 (en) *	2016-09-29	2024-06-01	Beijing Hanmi Pharmaceutical Co Ltd	Heterodimeric immunoglobulin constructs, pharmaceutical composition comprising the same, use and preparation methods thereof
AU2017359813B2 (en)	2016-11-18	2024-12-05	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-PD-1/anti-HER2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
US11739151B2 (en) *	2017-12-04	2023-08-29	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-PD-L1/anti-CD47 bispecific antibody
WO2019153200A1 (en) *	2018-02-08	2019-08-15	北京韩美药品有限公司	Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
AR117192A1 (en) *	2018-11-05	2021-07-21	Beijing Hanmi Pharmaceutical Co Ltd	HETERODIMERIC BI-SPECIFIC ANTIBODY SIMILAR IN STRUCTURE TO THE NATURAL ANTI-TNFa / ANTI-IL-17A ANTIBODY, AND METHOD FOR ITS PREPARATION
CN111196856A (en) *	2018-11-19	2020-05-26	三生国健药业（上海）股份有限公司	anti-HER 2/PD1 bispecific antibodies
CN111378045B (en) *	2018-12-28	2022-08-02	长春金赛药业有限责任公司	Bivalent and bispecific antibody, preparation method thereof, encoding gene, host cell and composition
WO2021023267A1 (en) *	2019-08-07	2021-02-11	信达生物制药(苏州)有限公司	Preparation comprising anti-pd-1/her2 bispecific antibody, and preparation method therefor and use thereof
CN111995685B (en) *	2020-04-30	2022-03-08	中国科学院上海药物研究所	Bispecific antibody targeting HER2 and PD-1 and application thereof
WO2024061223A1 (en) *	2022-09-20	2024-03-28	普米斯生物技术(珠海)有限公司	Antibody and use thereof in resisting tumor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9100352A (en)	1991-02-27	1992-09-16	Hoogovens Groep Bv	METHOD FOR MANUFACTURING IRON FOIL BY ELECTRODE POSITION.
US5731168A (en) *	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5869046A (en) *	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
DE69930424T2 (en) *	1998-05-06	2006-12-14	Genentech, Inc., South San Francisco	Anti-HER2 antibody composition
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2006031994A2 (en)	2004-09-14	2006-03-23	Xencor, Inc.	Monomeric immunoglobulin fc domains
CN102131828B (en)	2007-06-18	2015-06-17	默沙东有限责任公司	Antibodies to human programmed death receptor pd-1
WO2009089004A1 (en)	2008-01-07	2009-07-16	Amgen Inc.	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EA201171259A1 (en)	2009-04-22	2012-05-30	Мерк Патент Гмбх	ANTIBODY HYBRID PROTEINS WITH MODIFIED FCRN BINDING SITES
US9200060B2 (en)	2009-11-23	2015-12-01	Amgen Inc.	Monomeric antibody Fc
CN103429620B (en)	2010-11-05	2018-03-06	酵活有限公司	There is the antibody design of the stable heterodimeric of mutation in Fc domains
SG188638A1 (en)	2011-03-25	2013-05-31	Glenmark Pharmaceuticals Sa	Hetero-dimeric immunoglobulins
HUE037651T2 (en)	2011-04-20	2018-09-28	Medimmune Llc	Antibodies and other molecules that bind b7-h1 and pd-1
LT2771364T (en) *	2011-10-27	2019-09-10	Genmab A/S	Production of heterodimeric proteins
RU2675319C2 (en)	2011-11-04	2018-12-18	Займворкс Инк.	STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN Fc DOMAIN
MX360110B (en)	2012-04-20	2018-10-23	Merus Nv	Methods and means for the production of ig-like molecules.
IN2015MN00139A (en)	2012-09-25	2015-10-16	Glenmark Pharmaceuticals Sa
CA2889951C (en)	2012-11-02	2023-04-18	Zymeworks Inc.	Crystal structures of heterodimeric fc domains
US10077298B2 (en)	2012-11-28	2018-09-18	Zymeworks Inc.	Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9914785B2 (en)	2012-11-28	2018-03-13	Zymeworks Inc.	Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
RU2019118257A (en)	2012-12-03	2019-06-24	Новиммун С.А.	ANTI-CD47 ANTIBODIES AND METHODS OF THEIR APPLICATION
US9827309B2 (en) *	2013-08-20	2017-11-28	Merck Sharp & Dohme Corp.	Treating cancer with a combination of a PD-1 antagonist and dinaciclib
SG10201808519VA (en) *	2013-12-17	2018-10-30	Genentech Inc	Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
WO2015095412A1 (en)	2013-12-19	2015-06-25	Zhong Wang	Bispecific antibody with two single-domain antigen-binding fragments
TWI681969B (en)	2014-01-23	2020-01-11	美商再生元醫藥公司	Human antibodies to pd-1
JOP20200094A1 (en)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	Antibody molecules to pd-1 and uses thereof
JP6764858B2 (en)	2014-08-15	2020-10-07	メルクパテントゲーエムベーハー	SIRP-alpha immunoglobulin fusion protein
WO2016057933A1 (en)	2014-10-10	2016-04-14	Global Biopharma, Inc.	Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
WO2016109415A1 (en)	2014-12-30	2016-07-07	Celgene Corporation	Anti-cd47 antibodies and uses thereof
CA2973720A1 (en) *	2015-01-14	2016-07-21	Compass Therapeutics Llc	Multispecific immunomodulatory antigen-binding constructs
WO2016170039A1 (en)	2015-04-23	2016-10-27	F. Hoffmann-La Roche Ag	Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide
TW201709929A (en) *	2015-06-12	2017-03-16	宏觀基因股份有限公司	Combination therapy for the treatment of cancer
CN105111314B (en)	2015-08-13	2019-01-08	成都百世博生物技术有限公司	A kind of new fusion protein, pharmaceutical composition and its preparation method and application
CN105175545B (en)	2015-10-20	2019-01-25	安徽瀚海博兴生物技术有限公司	A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application
CN106883297B (en)	2015-12-16	2019-12-13	苏州康宁杰瑞生物科技有限公司	CH3 domain-based heterodimer molecule, preparation method and application thereof
CA3010027A1 (en)	2015-12-28	2017-07-06	Massachusetts Institute Of Technology	Bispecific antibodies having constant region mutations and uses therefor
WO2017167350A1 (en)	2016-03-30	2017-10-05	Horst Lindhofer	Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
GB201611530D0 (en)	2016-07-01	2016-08-17	Alligator Bioscience Ab	Novel polypeptides
IL265605B2 (en)	2016-09-29	2024-06-01	Beijing Hanmi Pharmaceutical Co Ltd	Heterodimeric immunoglobulin constructs, pharmaceutical composition comprising the same, use and preparation methods thereof
WO2018068336A1 (en)	2016-10-15	2018-04-19	Innovent Biologics (Suzhou) Co., Ltd	Pd-1 antibodies
AU2017359813B2 (en)	2016-11-18	2024-12-05	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-PD-1/anti-HER2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
EP3608341A4 (en)	2017-04-01	2021-01-06	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
AR112603A1 (en)	2017-07-10	2019-11-20	Lilly Co Eli	BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS
CN107325184A (en)	2017-08-08	2017-11-07	安徽大学	Bispecific antibody targeting EGFR and HER2 and application thereof
EA039662B1 (en)	2017-10-03	2022-02-24	Закрытое Акционерное Общество "Биокад"	Antibodies specific to cd47 and pd-l1
US11739151B2 (en)	2017-12-04	2023-08-29	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-PD-L1/anti-CD47 bispecific antibody
WO2019153200A1 (en)	2018-02-08	2019-08-15	北京韩美药品有限公司	Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
US11827697B2 (en)	2018-02-11	2023-11-28	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof

2017
- 2017-11-16 AU AU2017359813A patent/AU2017359813B2/en active Active
- 2017-11-16 JP JP2019527168A patent/JP7031810B2/en active Active
- 2017-11-16 BR BR112019010051A patent/BR112019010051A2/en active Search and Examination
- 2017-11-16 CN CN201780071590.9A patent/CN109963876B/en active Active
- 2017-11-16 MX MX2019005858A patent/MX2019005858A/en unknown
- 2017-11-16 EA EA201990894A patent/EA201990894A9/en unknown
- 2017-11-16 PE PE2019001036A patent/PE20191080A1/en unknown
- 2017-11-16 EP EP17871719.5A patent/EP3533804A4/en active Pending
- 2017-11-16 TN TNP/2019/000161A patent/TN2019000161A1/en unknown
- 2017-11-16 CA CA3043652A patent/CA3043652A1/en active Pending
- 2017-11-16 SG SG10201913260VA patent/SG10201913260VA/en unknown
- 2017-11-16 US US16/461,646 patent/US11319378B2/en active Active
- 2017-11-16 KR KR1020197013134A patent/KR102247704B1/en active IP Right Grant
- 2017-11-16 WO PCT/CN2017/111310 patent/WO2018090950A1/en active Application Filing
2019
- 2019-05-16 PH PH12019501089A patent/PH12019501089A1/en unknown
- 2019-05-17 CL CL2019001352A patent/CL2019001352A1/en unknown
- 2019-05-17 DO DO2019000124A patent/DOP2019000124A/en unknown
- 2019-05-17 EC ECSENADI201935482A patent/ECSP19035482A/en unknown
- 2019-05-17 CO CONC2019/0005101A patent/CO2019005101A2/en unknown

Also Published As

Publication number	Publication date
EA201990894A1 (en)	2019-09-30
TN2019000161A1 (en)	2020-10-05
CN109963876B (en)	2023-11-14
AU2017359813A1 (en)	2019-05-30
MX2019005858A (en)	2019-08-12
CN109963876A (en)	2019-07-02
KR20190065375A (en)	2019-06-11
JP2020510407A (en)	2020-04-09
JP7031810B2 (en)	2022-03-08
BR112019010051A2 (en)	2019-09-03
AU2017359813B2 (en)	2024-12-05
PE20191080A1 (en)	2019-08-20
EP3533804A4 (en)	2020-06-17
CL2019001352A1 (en)	2019-08-02
ECSP19035482A (en)	2019-05-31
CA3043652A1 (en)	2018-05-24
US11319378B2 (en)	2022-05-03
CO2019005101A2 (en)	2019-05-31
US20190367633A1 (en)	2019-12-05
EP3533804A1 (en)	2019-09-04
DOP2019000124A (en)	2019-11-15
WO2018090950A1 (en)	2018-05-24
PH12019501089A1 (en)	2020-03-02
EA201990894A9 (en)	2019-11-27
KR102247704B1 (en)	2021-05-03

Publication	Publication Date	Title
IL289946A (en)	2022-03-01	Bispecific antibodies against cd3 and cd20
SG10201913260VA (en)	2020-03-30	Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
IL279053A (en)	2021-01-31	Anti-pvrig/anti-tigit bispecific antibodies and methods of use
HK1258304A1 (en)	2019-11-08	Optimized anti-cd3 bispecific antibodies and uses thereof
ZA201900792B (en)	2020-03-25	Anti-pd-1 antibodies, method for producing same and method for using same
SG11201705252UA (en)	2017-07-28	Anti-pd-1 monoclonal antibodies and obtaining method thereof
IL283530A (en)	2021-07-29	Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
EP3527590A4 (en)	2020-05-27	Anti-egfr and anti-cd3 bispecific antibody and applications thereof
HK1251969A1 (en)	2019-05-10	Anti-her2 antibodies and methods of use
IL255076A0 (en)	2017-12-31	Bispecific antibody constructs for cdh3 and cd3
ZA201906457B (en)	2020-08-26	Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
ZA202004595B (en)	2024-09-25	Bispecific antibody construct directed to muc17 and cd3
EP3735429A4 (en)	2021-10-06	Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing same
IL269645A (en)	2019-11-28	Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
EP3645740A4 (en)	2021-08-18	Anti-pd-1 antibodies and methods of making and using thereof
ZA202003858B (en)	2021-07-28	Monoclonal antibodies and methods for using same
IL284026A (en)	2021-08-31	Methods of producing heterodimeric antibodies
EP3645738A4 (en)	2021-08-18	Anti-pd-l1 antibodies and methods of making and using thereof
IL271346A (en)	2020-01-30	Bispecific antibodies and methods of making and using thereof
EP3710482A4 (en)	2021-08-18	Compositions and methods for making and using bispecific antibodies
SG10201603290RA (en)	2017-11-29	Antibody Composition And Method For Producing The Same